This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Vertex (VRTX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex Pharmaceuticals' (VRTX) third-quarter earnings call, investors are most likely to focus on the sales performance of its triple combo CF drug Trikafta/Kaftrio and pipeline progress.
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Predict a 52% Upside in Exelixis (EXEL): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 52.2% in Exelixis (EXEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
New Strong Buy Stocks for October 26th
by Zacks Equity Research
HCCI, PKX, DFH, EXEL, and FAF have been added to the Zacks Rank #1 (Strong Buy) List on October 26, 2021.
Novartis (NVS) Q3 Earnings Beat, Sandoz Under Strategic Review
by Zacks Equity Research
Novartis (NVS) reports mixed results in the third quarter, as key brands maintain momentum but generics business remains weak.
Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exelixis (EXEL) Well Poised on Label Expansions of Caboemtyx
by Zacks Equity Research
The going has been good for Exelixis (EXEL) on label expansions of its lead drug, Cabometyx. The pipeline progress has been encouraging as well.
Biotech Stock Roundup: Regulatory Updates From BIIB, BMY, EXEL, Setback for VRCA
by Ekta Bagri
Regulatory and pipeline updates from pharma giants like Biogen (BIIB) and Bristol Myers (BMY) have been some of the key highlights in the biotech sector during the past week.
Bristol Myers (BMY) Opdivo-Relatlimab Combo Gets Priority Review
by Zacks Equity Research
Bristol Myers (BMY) application for fixed-dose combination of LAG-3-blocking antibody relatlimab and immuno- oncology Opdivo gets priority review in the United States.
Exelixis (EXEL) Gets FDA Nod for Cabometyx for Thyroid Cancer
by Zacks Equity Research
Exelixis (EXEL) gets FDA approval for a label expansion of Cabometyx for the treatment of locally advanced or metastatic differentiated thyroid cancer.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Biotech Stock Roundup: MRNA Vaccine Updates, Other Regulatory News & Collaborations
by Zacks Equity Research
Regulatory and pipeline updates from Moderna (MRNA) and CureVac (CVAC) among others were in focus in the biotech industry over the past week.
Exelixis (EXEL) Expands Oncology Collaboration With Invenra
by Zacks Equity Research
Exelixis (EXEL) expands collaboration with Invenra to include an additional 20 targets for multi-specific antibody, antibody-drug conjugate, and other biologic candidate discovery and development.
Exelixis (EXEL) Beats on Q2 Earnings & Revenues, Ups Sales View
by Zacks Equity Research
Exelixis (EXEL) beats on both earnings and revenues in the second quarter. Both figures increase on a year-over-year basis.
Exelixis (EXEL) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 500.00% and 29.99%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Exelixis (EXEL) Q2 Earnings Expected to Decline
by Zacks Equity Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for July 27th
by Zacks Equity Research
ARR, BCC, DK, EXEL and FCCO have been added to the Zacks Rank #5 (Strong Sell) List on July 27, 2021.
Biotech Stock Roundup: NTLA Surges on Study Data, EXEL & ALT Down on Updates & More
by Zacks Equity Research
The biotech sector was in focus last week with pipeline updates from Intellia (NTLA), Exelixis (EXEL) and Regeneron (RGEN), among others.
Exelixis (EXEL) Down on Data from Ongoing Liver Cancer Study
by Zacks Equity Research
Exelixis (EXEL) and partner announce unimpressive data from the late-stage COSMIC-312 study in patients with previously untreated advanced hepatocellular carcinoma.
Exelixis (EXEL) & Bristol Myers Team Up for Genitourinary Cancers
by Zacks Equity Research
Exelixis (EXEL) collaborates with Bristol Myers to evaluate its next-generation tyrosine kinase inhibitor in combination with immuno-oncology therapies in advanced solid tumors.
Exelixis (EXEL) Reports Encouraging Data From Prostate Cancer Study
by Zacks Equity Research
Exelixis (EXEL) announces encouraging results from the cohort 6 of a phase Ib study of Cabometyx in combination with Tecentriq.
Bristol Myers (BMY) Announces New Data on Cardiovascular Candidate
by Zacks Equity Research
Bristol Myers (BMY) announces new positive data on mavacamten from a late-stage study at the American College of Cardiology's 70th Annual Scientific Session.
Exelixis (EXEL) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Exelixis (EXEL) missed on earnings in the first quarter but beats on revenues.
Exelixis (EXEL) Reports Break-Even Earnings for Q1
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of -100.00% and 0.47%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?